You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR CARBACHOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Carbachol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00357864 ↗ Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow Completed Danish Headache Center 2006-07-01 To investigate headache score and accompanying symptoms during and after infusion of carbachol.
NCT00564408 ↗ Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients Completed Danish Headache Center N/A 2007-08-01 The purpose of this study is to test if carbachol infusion induces headache in migraine subjects as well as intra- and extra-cerebral vasodilatation.
NCT00861211 ↗ Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects Completed Icagen Phase 2 2008-10-01 The purpose of the study is to determine whether senicapoc can decrease changes in FEV1 following allergen challenge in atopic allergic subjects.
NCT02807415 ↗ ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor Completed Heidelberg University 2016-06-01 The academic investigator - initiated trial will evaluate in a postapproval setting whether, and if yes, to what extent and variability, the treatment with lumacaftor in combination with ivacaftor reverses the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous subjects with cystic fibrosis under real life conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carbachol

Condition Name

Condition Name for Carbachol
Intervention Trials
Presbyopia 3
Headache 2
Atopic Asthma 1
Cystic Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carbachol
Intervention Trials
Presbyopia 3
Headache 2
Fibrosis 1
Cystic Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carbachol

Trials by Country

Trials by Country for Carbachol
Location Trials
Denmark 2
United States 2
Germany 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carbachol
Location Trials
Tennessee 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carbachol

Clinical Trial Phase

Clinical Trial Phase for Carbachol
Clinical Trial Phase Trials
Phase 3 2
Phase 2 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carbachol
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carbachol

Sponsor Name

Sponsor Name for Carbachol
Sponsor Trials
Visus Therapeutics 3
Danish Headache Center 2
Heidelberg University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carbachol
Sponsor Trials
Other 8
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Carbachol: Clinical Trials, Market Analysis, and Projections

Introduction to Carbachol

Carbachol is a small molecule drug that acts as a cholinergic receptor agonist, primarily used in ophthalmic applications. It is known for its ability to induce miosis (pupillary constriction) and reduce intraocular pressure, making it a valuable agent in surgical and post-surgical eye care[5].

Clinical Trials Update

Ongoing and Completed Trials

Carbachol is currently being investigated in various clinical trials, particularly in the context of presbyopia and other ophthalmic conditions.

  • Brimochol PF Trials: A significant development involves the combination therapy Brimochol PF, which includes carbachol and brimonidine tartrate. The BRIO-I Phase 3 clinical trial has shown promising results, with Brimochol PF demonstrating superiority over both carbachol and brimonidine monotherapies in treating presbyopia. Up to 51% of subjects met the FDA's preset endpoint of a ≥ 15-letter gain in visual acuity. The second pivotal study, BRIO-II, is expected to be completed in 2025[1][4].

Mechanism and Indications

Carbachol's mechanism as a cholinergic receptor agonist allows it to stimulate muscarinic and nicotinic receptors, which is crucial for its ophthalmic applications. It is indicated for inducing miosis during surgery and reducing intraocular pressure elevations after cataract surgery[5].

Market Analysis

Global Market Size and Projections

The global carbachol market is expected to grow steadily over the next few years. Here are some key market projections:

  • Forecasted Market Size: The global carbachol market is projected to reach $324.5 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.1% from 2024 to 2030[2].
  • Regional Market Segmentation: The market is segmented by region, with North America, Europe, Asia Pacific, South America, and the Middle East and Africa being key areas. The report provides detailed market sizes and forecasts for each region[2].

Market Segmentation by Type and Application

  • Type: The market is segmented into different packaging types, such as 10 vials/box and 5 vials/box. The sales volume and revenue for each type are provided in the report[2].
  • Application: Carbachol is used in various settings, including hospitals and pharmacies. The report details the sales volume and revenue by application, helping businesses understand the market dynamics better[2].

Competitive Landscape

The global carbachol market is competitive, with key players such as Bausch and Lomb, Alcon, and Novartis Pharma. The report provides profiles of these companies, their market ranks, and technological trends, which are essential for understanding the competitive situation and making informed business decisions[2].

Technological Trends and New Product Developments

The carbachol market is driven by advancements in ophthalmic treatments and the need for effective and safe therapeutic options.

  • Combination Therapies: The success of combination therapies like Brimochol PF highlights the trend towards developing more effective and convenient treatments. Such combinations can offer better outcomes and patient compliance compared to monotherapies[4].
  • Clinical Trials: Ongoing clinical trials, such as the BRIO-I and BRIO-II studies, are crucial for expanding the therapeutic indications of carbachol and improving its efficacy and safety profile[1][4].

Impact of COVID-19 Pandemic

The COVID-19 pandemic has emphasized the importance of agile and responsive pharmaceutical companies. It has accelerated the need for efficient vaccine development and robust supply chain management, which indirectly benefits the carbachol market by highlighting the critical role of pharmaceuticals in public health[2].

Key Players and Market Ranks

The global carbachol market is dominated by several key players:

  • Bausch and Lomb: Known for its extensive portfolio in ophthalmic products.
  • Alcon: A major player in the eye care industry with a wide range of ophthalmic solutions.
  • Novartis Pharma: A global pharmaceutical company with significant investments in ophthalmology[2].

Market Challenges and Opportunities

Challenges

  • Regulatory Hurdles: For combination therapies like Brimochol PF, demonstrating the contribution of each component to the therapeutic effect is a significant regulatory challenge[4].
  • Competitive Landscape: The market is highly competitive, with several established players, making it challenging for new entrants to gain market share[2].

Opportunities

  • Growing Demand for Ophthalmic Treatments: The increasing prevalence of eye disorders such as presbyopia and glaucoma presents a growing demand for effective ophthalmic treatments like carbachol[2].
  • Advancements in Combination Therapies: The success of combination therapies offers opportunities for innovation and expansion in the carbachol market[4].

Conclusion

Carbachol remains a vital drug in ophthalmic care, with ongoing clinical trials and market projections indicating a promising future.

"Results of the BRIO-I study... give us reason for great optimism about this drug in particular and the future of medical presbyopia correction more generally."[4]

Key Takeaways

  • Clinical Trials: Brimochol PF, a combination therapy including carbachol, has shown promising results in treating presbyopia.
  • Market Growth: The global carbachol market is projected to reach $324.5 million by 2030, with a CAGR of 4.1% from 2024 to 2030.
  • Market Segmentation: The market is segmented by region, type, and application, with key players like Bausch and Lomb, Alcon, and Novartis Pharma.
  • Technological Trends: Combination therapies and ongoing clinical trials are driving the market forward.
  • Challenges and Opportunities: Regulatory hurdles and a competitive landscape are balanced by growing demand for ophthalmic treatments and innovation in combination therapies.

FAQs

What is the primary use of carbachol in ophthalmology?

Carbachol is primarily used to induce miosis during surgery and to reduce intraocular pressure elevations after cataract surgery[5].

What is the current status of the BRIO-I and BRIO-II clinical trials for Brimochol PF?

The BRIO-I trial has completed and shown promising results, while the BRIO-II trial is expected to be completed in 2025[1][4].

What is the forecasted market size for carbachol by 2030?

The global carbachol market is projected to reach $324.5 million by 2030, growing at a CAGR of 4.1% from 2024 to 2030[2].

Who are the key players in the global carbachol market?

Key players include Bausch and Lomb, Alcon, and Novartis Pharma[2].

How has the COVID-19 pandemic impacted the carbachol market?

The pandemic has highlighted the need for pharmaceutical companies to be agile and responsive to emerging public health needs, indirectly benefiting the carbachol market by emphasizing the importance of efficient pharmaceutical development and supply chain management[2].

Sources

  1. Patsnap Synapse: Carbachol - Drug Targets, Indications, Patents.
  2. QYResearch: Global Carbachol Market Research Report 2024.
  3. MedCityNews: AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials.
  4. Ophthalmology Times: Study offering new hope for medical presbyopia correction.
  5. DrugBank Online: Carbachol: Uses, Interactions, Mechanism of Action.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.